drugset
drugset / Trial / NCT01353404

Relative Bioavailability Study of Lipidil® Supra (Fenofibrate 160mg) Versus SYO-0805 (Fenofibrate 65mg)

NCT01353404 ↗

Phase 1 Completed 24 enrolled Samyang Biopharmaceuticals Corporation
RandomizedCrossoverOpen-labelTreatment

Summary

The purpose of this study is to evaluate the bioequivalence of Lipidil® Supra (fenofibrate 160mg) versus SYO-0805 (fenofibrate 65mg) in single dose oral administration.

Timeline

Start
2011-06
Primary completion
2011-08
Completion
2011-08

Drugs

EvaluationDrugModalityDoseRoute
Subject Fenofibrate Small molecule 65 mg Oral
Subject Fenofibrate Small molecule 160 mg Oral

Indications

hyperlipidemia